Tirzepatide’s potential benefits and risks for people with obstructive sleep apnea

A variety of therapies are used to treat OSA, and each has advantages and disadvantages of its own. Regardless of body weight, continuous positive airway pressure (CPAP) is the gold standard for quickly and reliably relieving airway blockage. However, discomfort, inconvenience, and mask intolerance are major obstacles that prevent long-term compliance. In mild-to-moderate OSA, oral appliances, such as mandibular advancement splints, provide a less invasive option and have been shown to be effective; however, in severe cases, their effectiveness decreases, and they may cause temporomandibular discomfort. Many patients, particularly those with structural deformities, may benefit from upper airway surgery; however, results are not always consistent, and the risks are significant. Although patient compliance is unpredictable, lifestyle modification, which includes weight loss, exercise, and alcohol abstinence, is crucial and maintaining long-term weight loss is notoriously challenging. [] ³

Tirzepatide (zepbound), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1), was initially developed for type 2 diabetes and later approved for weight management. Increasing satiety, decreasing caloric intake, and improving insulin sensitivity result in significant weight loss. With a half-life of approximately 5 days, it is typically administered subcutaneously, enabling once-weekly dosing to maintain steady therapeutic levels. Obesity has been suggested as a possible treatment option because it is the most significant modifiable risk factor for OSA. Given this, the recent FDA approval of tirzepatide has sparked a lot of excitement and media coverage as a potentially "game-changing" pharmaceutical option; however, before such enthusiasm is warranted, its role in managing OSA necessitates a careful evaluation of the supporting data. [] ⁵ [] ⁶

Initial trials suggest small decreases in the apnoea-hypopnoea index (AHI) and enhanced sleep architecture in people who lose significant weight with the drug. However, these effects are secondary and not related to the upper airway pathology that causes OSA. This indirect way of action poses a significant therapeutic constraint. OSA is primarily a mechanical airway condition rather than a metabolic problem; however, the two can overlap. While losing weight can lower the severity of OSA, it seldom cures the condition, particularly in people with anatomical or neuromuscular predispositions. Using a metabolic medication to treat a structural issue results in a mismatch between mechanism and disease target. [] ⁷ [] ⁷ [] ⁸

The absence of long-term data on AHI following tirzepatide cessation is a critical limitation, as weight regain is a common occurrence after discontinuing weight loss medications, potentially leading to a recurrence of OSA symptoms. A systematic review and meta-analysis revealed that individuals who discontinued semaglutide or tirzepatide experienced an average weight regain of 9.69 kg. This rapid weight regain may negate the metabolic benefits initially observed during treatment. [] ⁹ [] ¹⁰

Moreover, the safety profile of tirzepatide cannot be overlooked. Side effects include nausea, vomiting, and diarrhea; acute pancreatitis, cholelithiasis, or cholecystitis, and possible thyroid tumor growth add further complexity to long-term usage. Patients with OSA are often multimorbid, and adding another chronic medication with potential systemic risks requires careful clinical judgement. [,] ^{11 12}

Tirzepatide may be best used as an adjunct in the context of comprehensive OSA care rather than as a substitute. Pharmacological weight loss will lessen the degree of disease in patients who are not responsive to CPAP and can augment results with mandibular devices or positional therapy. Tirzepatide may improve general outcomes and cardiometabolic comorbidities among obese users of CPAP, adding to rather than substituting the gold-standard treatment. Long-term weight gain may be reduced by tirzepatide, which will assist in producing longer results when combined with structured behavioral programs. The optimal way forward is anticipated to be integrated management strategies combining medication, mechanical therapies, and lifestyle interventions. [] ¹³

Given its revolutionary potential, artificial intelligence (AI) has a bright future in clarifying tirzepatide's role in OSA. Conventional parameters, such as weight loss or AHI decline, only provide a limited view of the therapeutic effect. AI-driven approaches that use machine learning to integrate multi-omics data, clinical phenotypes, and upper airway imaging can help predict adherence, find new response indicators, and identify patients who are most likely to benefit. Multi-omics analysis could classify responders based on metabolic profiles, while AI-driven imaging could evaluate structural airway changes after pharmacologically induced weight loss.

AI models like AlphaFold have revolutionized structural biology and drug discovery, going beyond patient stratification. Large language models are also performing well in clinical decision support and medical diagnostics. By directing integrated therapy design and dynamic treatment pathways, integrating these tools into OSA research may hasten the transition away from empirical, one-size-fits-all approaches and toward precision medicine. [,] ^{14 15}

Well-designed trials investigating the appropriateness of tirzepatide when added to proven therapies such as CPAP, mandibular advancement devices or upper airway stimulation are needed. There is a need for longitudinal studies to determine the duration of OSA improvement after discontinuation of medication and to develop strategies that prevent rebound weight gain. In addition to weight loss, studies need to investigate in a mechanistic manner whether tirzepatide has a direct effect on upper airway neuromuscular tone. Finally, AI-guided approaches could enhance precision therapy in the field by pinpointing optimal patient subgroups, predicting therapy response and designing personalized models of OSA management.

In conclusion, tirzepatide represents a welcome pharmacologic advance in the management of OSA that is related to obesity; however, its effects appear to be largely weight-related and are not intended to replace efficacious mechanical therapies. Prudent applications are necessary due to safety, compliance and therapeutic oversimplifications. An integrated, multimodal approach that involves behavioral, mechanical and pharmacologic interventions with AI-enabled precision medicine will yield long-lasting, personalized results for treating OSA.